Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, and its news flow reflects the progress and challenges of advancing a pipeline in oncology. Company updates frequently highlight developments in its lead programs, including BDC-3042, a first-in-class agonist antibody targeting dectin-2 on tumor-associated macrophages, and BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2.
On this page, readers can follow BOLT news related to clinical trial milestones, preclinical data presentations, and collaboration activities. Press releases have detailed Phase 1 dose-escalation results for BDC-3042 in patients with advanced solid tumors, including safety, pharmacokinetics, and early signs of anti-tumor activity. Other announcements describe the opening and conduct of the BDC-4182 Phase 1 study in gastric and gastroesophageal cancer, protocol updates such as the introduction of step-up dosing, and expectations for future clinical data readouts as disclosed by the company.
News items also cover preclinical Boltbody ISAC programs targeting CEA and PD-L1, with data presented at major scientific meetings like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). These releases summarize findings such as complete tumor regressions in animal models, induction of immunological memory, and favorable toxicology profiles in non-human primates.
In addition, Bolt Biotherapeutics issues regular financial results and business updates, including quarterly and annual earnings releases, cash runway commentary, and information about restructuring actions intended to reduce operating expenses. Collaboration updates with partners such as Genmab and Toray, as well as participation in investor and scientific conferences, are also common topics. Investors and observers can use this news feed to track how Bolt Biotherapeutics’ clinical, preclinical, and corporate activities evolve over time.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced its participation in two major healthcare conferences this March. The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST. Additionally, Bolt's management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 10, 2025.
Bolt Biotherapeutics (BOLT) announced that Caprin-1 is the target of their worldwide co-development collaboration with Toray Industries. The partners are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types.
Under the agreement, Toray provides proprietary antibodies targeting Caprin-1, including TRK-950, while Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform. Caprin-1 is a tumor-specific antigen highly expressed on solid tumors with minimal presence in normal tissues, and contributes to tumor growth and metastases. Toray's TRK-950 antibody is currently in Phase 2 development for Gastric cancer.
Bolt Biotherapeutics (BOLT) reported Q3 2024 financial results, highlighting progress in its cancer immunotherapy programs. The company advanced to the highest dose level in BDC-3042's Phase 1 trial and presented updated preclinical data for BDC-4182 at SITC. Q3 revenue was $1.1 million, down from $2.5 million in Q3 2023. R&D expenses decreased to $13.8 million from $15.0 million, while G&A expenses reduced to $3.8 million from $5.8 million. The company reported an operational loss of $16.4 million. With $84.4 million in cash, funding is expected to last through mid-2026.
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstrating anti-tumor activity across various models and acceptable safety in non-human primates. The company plans to initiate clinical trials in 2025. The Phase 1 BDC-1001 trial revealed that greater immune activation was associated with clinical benefit, particularly in patients with high HER2 antigen expression, supporting the development of next-generation ISACs with enhanced immune activation.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.
Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:
1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.
2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.
Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Advancement to cohort 6 in the Phase 1 study of BDC-3042 for advanced cancers.
2. Acceptance of an abstract for BDC-4182, a claudin 18.2-targeting Boltbody ISAC, at the SITC 39th Annual Meeting.
3. Cash balance of $97.5 million as of June 30, 2024, expected to fund operations through mid-2026.
4. Q2 2024 financial results: Collaboration revenue of $1.3 million, R&D expenses of $15.4 million, G&A expenses of $4.9 million, and a loss from operations of $22.6 million.
5. Ongoing collaborations with Genmab and Toray continue to progress.
Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.
Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.
Summary not available.
Summary not available.